# Endoscopic sclerotherapy compared with no specific treatment for the primary prevention of bleeding from oesophageal varices: a randomised controlled multicentre trial

<ul><li>Prospectively registered</li></ul>		
Protocol		
Statistical analysis plan		
Results		
ndividual participant data		

### Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

### Contact name

Dr Henk R. van Buuren

### Contact details

Erasmus MC
University Medical Centre Rotterdam
PO BOX 3000
Rotterdam
Netherlands
2040 CA
+31 (0)10 463 3041
h.vanbuuren@erasmusmc.nl

# Additional identifiers

**EudraCT/CTIS** number

IRAS number

ClinicalTrials.gov number

# Secondary identifying numbers

90/006

# Study information

### Scientific Title

### **Study objectives**

To compare endoscopic sclerotherapy (ES) with no specific treatment for the primary prevention of bleeding from oesophageal varices in patients with cirrhosis.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

### Study type(s)

Treatment

### Participant information sheet

### Health condition(s) or problem(s) studied

Liver cirrhosis

### **Interventions**

Prophylactic sclerotherapy versus no specific treatment.

For more information, please contact the College voor Zorgverzekeringen (Health Care Insurance Board) on infoSBA@cvz.nl.

### Intervention Type

Other

### Phase

**Not Specified** 

### Primary outcome measure

Not provided at time of registration

### Secondary outcome measures

Not provided at time of registration

### Overall study start date

01/05/1986

### Completion date

31/05/1993

# **Eligibility**

### Key inclusion criteria

- 1. Adults with endoscopically documented grade II, III or IV oesophageal varices
- 2. Absence of prior bleeding from varices
- 3. Evidence of active and/or progressive liver disease (e.g. as indicated by repeatedly elevated serum transaminases or increasing serum bilirubin levels or development of ascites within the past year)
- 4. Documented increase in the size of oesophageal varices
- 5. All patients gave informed consent

### Participant type(s)

Patient

### Age group

Adult

### Sex

Both

### Target number of participants

166

### Key exclusion criteria

- 1. Use of beta-blockers and nitrates
- 2. Malignancy
- 3. Haemophilia
- 4. Age older than 70 75 years
- 5. No opportunity for follow-up visits

### Date of first enrolment

01/05/1986

### Date of final enrolment

31/05/1993

# Locations

### Countries of recruitment

Netherlands

# Study participating centre

**Erasmus MC** 

Rotterdam Netherlands 2040 CA

# Sponsor information

### Organisation

Dutch Health Care Insurance Board (College voor Zorgverzekeringen) (The Netherlands)

### Sponsor details

PO Box 320 Diemen Netherlands 1110 AH +31 (0)20 7978555 Info@cvz.nl

### Sponsor type

Government

# Funder(s)

## Funder type

Government

### **Funder Name**

Dutch Health Care Insurance Board (College Voor Zorgverzekeringen) (The Netherlands) (ref: OG 90/006)

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

# Intention to publish date

# Individual participant data (IPD) sharing plan

**IPD sharing plan summary**Not provided at time of registration

# Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	15/08/2003		Yes	No